Aurobindo Pharma Q4 FY26 Results & Board Decisions

• Approved standalone and consolidated audited financial results for Q4 and year ended March 31, 2026, with unmodified audit opinion from Deloitte.
• Reported standalone net profit of ₹6,922.3 million for Q4 FY26 and consolidated net profit attributable to owners of ₹9,212.6 million for the same period.
• Completed ₹8,000 million equity share buyback and approved transfer of domestic branded generics business to subsidiary Auropharm Limited.
• Appointed M/s. RPR & Associates as new Secretarial Auditors and reappointed Ernst & Young LLP as Internal Auditors.